Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 410

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Open access
Garcia-Murillas, Isaac, Chopra, Neha, Comino-Méndez, Iñaki, Beaney, Matthew, Tovey, Holly, Cutts, Rosalind J., Swift, Claire, Kriplani, Divya, Afentakis, Maria, Hrebien, Sarah, Walsh-Crestani, Giselle, Barry, Peter, Johnston, Stephen R. D., Ring, Alistair, Bliss, Judith, Russell, Simon, Evans, Abigail, Skene, Anthony, Wheatley, Duncan, Dowsett, Mitch, Smith, Ian E., Turner, Nicholas C.·2019·JAMA Oncology

Abstract

Importance: Current treatment cures most cases of early-stage, primary breast cancer. However, better techniques are required to identify which patients are at risk of relapse. Objective: To assess the clinical validity of molecular relapse detection with circulating tumor DNA (ctDNA) analysis in early-stage breast cancer. Design, Setting, and Participants: This prospective, multicenter, sample collection, validation study conducted at 5 United Kingdom medical centers from November 24, 2011, to October 18, 2016, assessed patients with early-stage breast cancer irrespective of hormone receptor and ERBB2 (formerly HER2 or HER2/neu) status who were receiving neoadjuvant chemotherapy followed by surgery or surgery before adjuvant chemotherapy. The study recruited 170 women, with mutations identified in 101 patients forming the main cohort. Secondary analyses were conducted on a combined cohort of 144 patients, including 43 patients previously analyzed in a proof of principle study. Interventions: Primary tumor was sequenced to identify somatic mutations, and personalized tumor-specific digital polymerase chain reaction assays were used to monitor these mutations in serial plasma samples taken every 3 months for the first year of follow-up and subsequently every 6 months. Main Outcomes and Measures: The primary end point was relapse-free survival analyzed with Cox proportional hazards regression models. Results: In the main cohort of 101 female patients (mean [SD] age, 54 [11] years) with a median follow-up of 35.5 months (interquartile range, 27.9-43.0 months), detection of ctDNA during follow-up was associated with relapse (hazard ratio, 25.2; 95% CI, 6.7-95.6; P < .001). Detection of ctDNA at diagnosis, before any treatment, was also associated with relapse-free survival (hazard ratio, 5.8; 95% CI, 1.2-27.1; P = .01). In the combined cohort, ctDNA detection had a median lead time of 10.7 months (95% CI, 8.1-19.1 months) compared with clinical relapse and was associated with relapse in all breast cancer subtypes. Distant extracranial metastatic relapse was detected by ctDNA in 22 of 23 patients (96%). Brain-only metastasis was less commonly detected by ctDNA (1 of 6 patients [17%]), suggesting relapse sites less readily detectable by ctDNA analysis. Conclusions and Relevance: The findings suggest that detection of ctDNA during follow-up is associated with a high risk of future relapse of early-stage breast cancer. Prospective studies are needed to assess the potential of molecular relapse detection to guide adjuvant therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2019.1838

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 410

Metadata

Authors
Garcia-Murillas, I., Chopra, N., Comino-Méndez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., Walsh-Crestani, G., Barry, P., Johnston, S. R. D., Ring, A., Bliss, J., Russell, S., Evans, A., Skene, A., Wheatley, D., Dowsett, M., Smith, I. E., & Turner, N. C.
Venue
JAMA Oncology
Published
2019-10-01
Volume
5
Issue
10
Pages
1473
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2964980115
Cited by
410
References
15
FWCI
12.16
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. https://app.cochat.ai/papers/10.1001/jamaoncol.2019.1838
The paper
Garcia-Murillas, I., Chopra, N., Comino-Méndez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., Walsh-Crestani, G., Barry, P., Johnston, S. R. D., Ring, A., Bliss, J., Russell, S., Evans, A., Skene, A., Wheatley, D., . . . Turner, N. C. (2019). Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.1838

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.